|
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases
|
Apr 2023
|
Internal and Emergency Medicine
|
myelodysplastic syndromes (MDS)
|
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
|
Apr 2023
|
Current Hematologic Malignancy Reports
|
myelodysplastic syndromes (MDS)
|
|
PNH and complement gene variants
|
Apr 2023
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study
|
Apr 2023
|
Journal of Hematology & Oncology
|
myelodysplastic syndromes (MDS)
|
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
|
Apr 2023
|
Blood Cancer
|
myelodysplastic syndromes (MDS)
|
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Apr 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Apr 2023
|
American Journal of Hematology
|
aplastic anemia
|
